PeptideStack
5.2kquestions
20kanswers
220users

Is SURMOUNT-1 a fair comparison of liraglutide against its comparator arm?

Asked 18 Jul 2026Modified 12 days agoViewed 560 times
3

Concretely: SURMOUNT-1 · liraglutide.

The claim is plausible, which is exactly why I want to check it.

I am able to read a paper if someone points me at one.

Can anyone point me at a primary source, or confirm that there is not one?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
FC
askedfiadh_cronin14k2818 Jul 2026

No answers yet

This question has not been answered. It has been viewed 560 times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.